Home › Research › Biomarkers
Chronic Migraine and Alzheimer’s Dementia: A Candidate Mechanistic Route, and the Evidence That Would Test It
Sulter GA.. Preprints.org, 2026-08-20
Topic: Brain imaging, connectivity and assessment
Plain-language summary
The association declines monotonically as control over ascertainment improves. For primary headache the odds ratio is 1.49 (95% CI 1.20–1.85) in case-control studies, 1.35 (1.25–1.45) in retrospective cohorts and 0.82 (0.74–0.92) in prospective cohorts, the last significantly below the null. Heterogeneity falls from I2 85.9% undivided to 9.2%, 61.9% and 26.9% within design strata, and small-study effects appear only in the middle stratum. Attack frequency has never been related to dementia incidence in any cohort; the one study that measured frequency directly reported no direct association with its brain-age gap, alongside a positive indirect path through segmented brain volume in a design with a truncated exposure range. Chronicity has never been stratified against episodic migraine. No adequate aura-stratified evidence exists, so aura supports neither the model nor its negation. Across pain phenotypes migraine ranks fifth of six, below trigeminal neuralgia and fibromyalgia, neither of which involves depolarization, and the source authors attribute their own top-ranked estimate to depression. Risk attenuates with time since the first diagnostic code and remains elevated beyond ten years. These findings share one cause: exposure is recorded as a diagnosis and not measured as disease activity, so the coded date marks clinical contact and not disease onset, and the interval between the two differs systematically across phenotypes and designs. The proposition is untested, not refuted. A falsifiable prediction follows, together with a cross-sectional plasma-biomarker comparison that would substantially weaken the hypothesis if null and open the frequency question if positive, at a fraction of the cost of an imaging program. Plain Language Summary: Migraine has been named as a possible cause of dementia in later life, but no long-term study has asked whether people with more attacks go on to develop it. We reviewed the evidence and found the link weakens, then reverses, in the studies that follow patients most closely. These studies record a diagnosis and not the illness itself, so the question stays open; one blood test study would go a long way toward answering it.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Sulter, G. A. (2026). Chronic Migraine and Alzheimer’s Dementia: A Candidate Mechanistic Route, and the Evidence That Would Test It. Preprints.org. https://doi.org/10.20944/preprints202605.0132.v2
Vancouver
Sulter GA. Chronic Migraine and Alzheimer’s Dementia: A Candidate Mechanistic Route, and the Evidence That Would Test It. Preprints.org. 2026. doi:10.20944/preprints202605.0132.v2.
BibTeX
@article{sulter2026-8b77381d,
author = {Sulter, G. A.},
title = {{Chronic Migraine and Alzheimer’s Dementia: A Candidate Mechanistic Route, and the Evidence That Would Test It}},
journal = {Preprints.org},
year = {2026},
doi = {10.20944/preprints202605.0132.v2},
url = {https://doi.org/10.20944/preprints202605.0132.v2}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The association declines monotonically as control over ascertainment improves.
- For primary headache the odds ratio is 1.49 (95% CI 1.20–1.85) in case-control studies, 1.35 (1.25–1.45) in retrospective cohorts and 0.82 (0.74–0.92) in prospective cohorts, the last significantly below the null.
- Heterogeneity falls from I2 85.9% undivided to 9.2%, 61.9% and 26.9% within design strata, and small-study effects appear only in the middle stratum.
- Attack frequency has never been related to dementia incidence in any cohort; the one study that measured frequency directly reported no direct association with its brain-age gap, alongside a positive indirect path through segmented brain volume in a design with a truncated exposure range.
- Chronicity has never been stratified against episodic migraine.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcase-control study
- Effect size85.9%; 9.2%; 61.9%
- Evidence strengthModerate
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 37 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for sample size, studied in people and randomized / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 23 of the 62 points we could judge it on, which is 37 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (Preprints.org) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 6 / 12 | A case-control study |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 23 / 62 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 23 of the 62 points we could judge it on is 37 out of 100. |
| Total | 37 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “metabolic-syndrome”
306 studies in the library carry the topic tag “metabolic-syndrome”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 306 tagged studies.